CSIMarket Company Name, Ticker, Suppliers, else..
 
Hcw Biologics Inc   (NASDAQ: HCWB)
 
Price: $2.8700 $-0.49 -14.456%
Day's High: $3.3399999141693115 Week Perf: -16.33 %
Day's Low: $ 2.70 30 Day Perf: -16.33 %
Volume (M): 126,610 52 Wk High: $ 6.44
Volume (M$): $ 0 52 Wk Avg: $2.11
Open: $3.34 52 Wk Low: $0.25



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 1
 Employees 35
 Revenues (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -21
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


HCW Biologics Inc. is a biopharmaceutical company that specializes in the research, development, and manufacturing of biotherapeutics and vaccines. The company focuses on utilizing innovative technologies and scientific processes to develop advanced treatments for various medical conditions. They aim to advance the field of biomedicine by creating safe and effective products that improve patient outcomes.


   Company Address: 2929 N Miramar 33025 FL
   Company Phone Number: 842-2024   Stock Exchange / Ticker: NASDAQ HCWB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        4.76% 
MRK        1.87% 
OGN        0.07% 
PFE        2.82% 
TEVA   -2.66%    
VRTX        1.9% 
• View Complete Report
   



Product Service News

Innovations in T-Cell Engagement HCW Biologics Unveils Preclinical Data at SITC 40th Annual Meeting

Published Fri, Nov 7 2025 1:11 PM UTC

In the rapidly evolving field of immunotherapy, HCW Biologics Inc. has made significant strides with the presentation of groundbreaking preclinical data for its tetra-valent T-cell engager programme at the Society for Immunotherapy of Cancers’ (SITC) 40th Annual Meeting. This latest development showcases the promising potential of HCW Biologics novel approach to T-cell en...
Product Service News

HCW Biologics Advances TRBC-Pembrolizumab-Based Immunotherapy Amidst Significant Revenue Decline and Competitor Growth

Published Tue, Sep 16 2025 12:32 PM UTC

In a pivotal move within the landscape of immunotherapy, HCW Biologics has announced the designation of its proprietary TRBC-Pembrolizumab-based immune checkpoint inhibitor as its flagship therapeutic for internal clinical development. This selection marks a significant step forward, as the lead product candidate is set to be advanced into late Investigational New Drug (IND)...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.56
Price to Sales (Expected) -
Price to Book 0.51
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.04
Working Capital Ratio 0.06
Leverage Ratio (MRQ) 2.6
Total Debt to Equity 0.88
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -60.42 $
Revenues (TTM) 5.15 $
Cash Flow (TTM) -
Cash 0.56 $
Book Value 5.59 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 195,509
Net Income per Employee (TTM) -611,719
Receivable Turnover Ratio (TTM) 175.24
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.26

Profitability Ratios Current
Gross Margin (MRQ) 10.82 %
Operating Margin (MRQ) -1230.59 %
Net Margin (MRQ) -5975.12 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Hcw Biologics Inc's Segments
Ancillary Service    5.06 % of total Revenue
Licensed IP    2451.36 % of total Revenue
Service    89.49 % of total Revenue
Single Reportable Segment    2545.91 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.